Vault-13

CHI Advisors LLC

NEW YORK, NY · CIK 1791468 · 13F filing filed 2022-08-12

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

$261.5m reported value +11.3% vs Q1 2022
25positions
82.9%in top 10
4 new 13 added 1 reduced 0 sold out vs Q1 2022

Options: 2 call positions ($9.0k notional), 1 put positions ($372.0k notional) – listed below, not included above.

Holdings, Q2 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 PROMETHEUS BIOSCIENCES INC COM COM 1,671,976 $47.2m18.05% 18.05% AddedShares held: Q3 2021 2.9m, Q4 2021 1.8m, Q1 2022 1.6m, Q2 2022 1.7m +86.9k +86,880 5.5%
2 CULLINAN THERAPEUTICS INC COM CGEM CGEM 3,047,609 $39.1m14.94% 14.94% AddedShares held: Q3 2021 2.2m, Q4 2021 2.5m, Q1 2022 2.8m, Q2 2022 3.0m +294.6k +294,562 10.7%
3 REPARE THERAPEUTICS INC COM RPTX RPTX 2,646,781 $37.0m14.16% 14.16% AddedShares held: Q3 2021 2.2m, Q4 2021 2.2m, Q1 2022 2.6m, Q2 2022 2.6m +65.7k +65,684 2.5%
4 PLIANT THERAPEUTICS INC COM PLRX PLRX 3,106,807 $24.9m9.52% 9.52% AddedShares held: Q3 2021 2.5m, Q4 2021 2.6m, Q1 2022 2.7m, Q2 2022 3.1m +449.4k +449,350 16.9%
5 VECTIVBIO HLDG AG ORD SHS ORD SHS 3,782,199 $20.4m7.81% 7.81% AddedShares held: Q3 2021 2.6m, Q4 2021 2.7m, Q1 2022 3.1m, Q2 2022 3.8m +697.9k +697,889 22.6%
6 KEZAR LIFE SCIENCES INC COM COM 1,840,793 $15.2m5.82% 5.82% AddedShares held: Q3 2021 75.0k, Q4 2021 272.2k, Q1 2022 314.6k, Q2 2022 1.8m +1.5m +1,526,181 485.1%
7 2SEVENTY BIO INC COMMON STOCK TSVT TSVT 819,672 $10.8m4.14% 4.14% UnchangedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 819.7k, Q2 2022 819.7k
8 INOZYME PHARMA INC COM COM 2,033,802 $9.7m3.71% 3.71% AddedShares held: Q3 2021 920.3k, Q4 2021 892.1k, Q1 2022 892.1k, Q2 2022 2.0m +1.1m +1,141,745 128.0%
9 COMPASS THERAPEUTICS INC COM CMPX CMPX 2,829,712 $7.5m2.87% 2.87% UnchangedShares held: Q3 2021 0, Q4 2021 3.0m, Q1 2022 2.8m, Q2 2022 2.8m
10 IKENA ONCOLOGY INC COM COM 1,090,937 $4.8m1.85% 1.85% AddedShares held: Q3 2021 315.0k, Q4 2021 814.8k, Q1 2022 814.8k, Q2 2022 1.1m +276.2k +276,182 33.9%
11 PRECISION BIOSCIENCES INC COM COM 3,003,751 $4.8m1.84% 1.84% AddedShares held: Q3 2021 646.7k, Q4 2021 606.6k, Q1 2022 606.6k, Q2 2022 3.0m +2.4m +2,397,122 395.1%
12 NKARTA INC COM NKTX NKTX 358,013 $4.4m1.69% 1.69% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 358.0k
13 FREELINE THERAPEUTICS HLDGS SPONSORED ADS SPONSORED ADS 4,862,319 $4.2m1.62% 1.62% UnchangedShares held: Q3 2021 1.4m, Q4 2021 1.9m, Q1 2022 4.9m, Q2 2022 4.9m
14 OMEGA THERAPEUTICS INC COMMON STOCK COMMON STOCK 1,055,882 $4.0m1.53% 1.53% UnchangedShares held: Q3 2021 1.1m, Q4 2021 1.1m, Q1 2022 1.1m, Q2 2022 1.1m
15 AKOUOS INC COM COM 836,120 $3.9m1.50% 1.50% UnchangedShares held: Q3 2021 858.0k, Q4 2021 836.1k, Q1 2022 836.1k, Q2 2022 836.1k
16 G1 THERAPEUTICS INC COM GTHX GTHX 767,235 $3.8m1.45% 1.45% AddedShares held: Q3 2021 50.0k, Q4 2021 230.0k, Q1 2022 488.6k, Q2 2022 767.2k +278.6k +278,600 57.0%
17 ORCHARD THERAPEUTICS PLC ADS ORTX ORTX 5,307,751 $3.1m1.19% 1.19% UnchangedShares held: Q3 2021 4.1m, Q4 2021 6.4m, Q1 2022 5.3m, Q2 2022 5.3m
18 ONCORUS INC COM COM 2,367,436 $3.0m1.14% 1.14% ReducedShares held: Q3 2021 1.8m, Q4 2021 2.1m, Q1 2022 2.4m, Q2 2022 2.4m -50.0k -50,000 -2.1%
19 LARIMAR THERAPEUTICS INC COM LRMR LRMR 1,515,148 $3.0m1.14% 1.14% UnchangedShares held: Q3 2021 1.5m, Q4 2021 1.5m, Q1 2022 1.5m, Q2 2022 1.5m
20 KEROS THERAPEUTICS INC COM KROS KROS 103,429 $2.9m1.09% 1.09% AddedShares held: Q3 2021 12.6k, Q4 2021 17.5k, Q1 2022 62.2k, Q2 2022 103.4k +41.2k +41,200 66.2%
21 CORVUS PHARMACEUTICALS INC COM CRVS CRVS 2,214,184 $2.2m0.84% 0.84% AddedShares held: Q3 2021 165.9k, Q4 2021 400.0k, Q1 2022 1.7m, Q2 2022 2.2m +511.0k +511,047 30.0%
22 ENTRADA THERAPEUTICS INC COM TRDA TRDA 163,496 $2.0m0.76% 0.76% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 163.5k
23 OVID THERAPEUTICS INC COM OVID OVID 864,822 $1.9m0.71% 0.71% AddedShares held: Q3 2021 233.5k, Q4 2021 400.0k, Q1 2022 852.9k, Q2 2022 864.8k +11.9k +11,934 1.4%
24 EIGER BIOPHARMACEUTICALS INC COM CLDN CLDN 190,000 $1.2m0.46% 0.46% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 190.0k
25 PHASEBIO PHARMACEUTICALS INC COM PHAS PHAS 750,000 $450.0k0.17% 0.17% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 750.0k

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
SPDR SER TR XBI · Put XBIPut 157,000 $372.0k157.0k shares Reduced
KEZAR LIFE SCIENCES INC Call Call 100,000 $5.0k100.0k shares New
EIGER BIOPHARMACEUTICALS INC CLDN · Call CLDNCall 25,100 $4.0k25.1k shares New